Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $84,465.77 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 3,191 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $84,465.77. Following the transaction, the insider owned 35,559 shares of the company’s stock, valued at $941,246.73. This represents a 8.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $84,350.43.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock traded up $0.34 during trading on Friday, hitting $26.21. 273,266 shares of the stock were exchanged, compared to its average volume of 637,671. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a 12 month low of $14.27 and a 12 month high of $53.65. The stock’s fifty day moving average is $28.74 and its 200 day moving average is $31.20. The stock has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). As a group, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the fourth quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the second quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. boosted its stake in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.

Analysts Set New Price Targets

MAZE has been the subject of several analyst reports. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $66.00.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.